Precigen, Inc. (PGEN) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Precigen, Inc. is a clinical-stage biopharmaceutical company focused on gene and cell therapies. The reporting period covers the three and six months ended June 30, 2025. The Company has streamlined its operations into a single segment, prioritizing the development and potential commercialization of PRGN-2012 (zopapogene imadenovec) for Recurrent Respiratory Papillomatosis (RRP). The FDA has granted priority review to the Biologics License Application (BLA) for PRGN-2012, with a PDUFA target action date of August 27, 2025. The Company also operates Exemplar Genetics, LLC, which provides miniature pig research models.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenues | $856 | $717 | $2,197 | $1,782 |
| Net Loss | $(26,642) | $(58,792) | $(80,795) | $(82,530) |
| Operating Loss | $(31,764) | $(60,841) | $(54,360) | $(85,251) |
| Cash & Cash Equivalents | $13,760 | $9,608 | $13,760 | $9,608 |
| Short-term Investments | $45,993 | $68,393 | $45,993 | $68,393 |
| Total Liquidity | $59,753 | $78,001 | $59,753 | $78,001 |
| Warrant Liabilities | $78,558 | $50,537 | $78,558 | $50,537 |
| Series A Preferred Stock (Mezzanine) | $30,883 | $28,218 | $30,883 | $28,218 |
Note: Amounts in thousands. Liquidity includes cash, cash equivalents, and short-term investments.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19.4% in Q2 2025 and 23.3% YTD 2025 compared to the prior year periods, driven primarily by increased product and service volumes from the Exemplar subsidiary.
- Expense Reductions: Research and Development (R&D) expenses decreased 26.8% in Q2 and 26.6% YTD, largely due to the shutdown of the ActoBio subsidiary and strategic prioritization of the clinical portfolio.
- SG&A Increase: Selling, General, and Administrative (SG&A) expenses increased 56.5% in Q2 and 39.3% YTD, attributed to costs associated with PRGN-2012 commercial readiness.
- Impairment Charges: The Company recorded a $3.9 million goodwill impairment charge in Q2 2025 related to the Exemplar reporting unit. This contrasts with a $32.9 million impairment of other noncurrent assets recorded in Q2 2024 related to the ActoBio shutdown.
- Warrant Liability Volatility: The fair value of warrant liabilities increased significantly, resulting in a $28.0 million non-cash expense YTD 2025 (compared to a $4.5 million non-cash gain in Q2 2025 alone). This was driven by an increase in the Company's stock price relative to the end of 2024.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern. Current cash and investments ($59.8 million) are insufficient to fund planned operations for one year without additional funding or revenue from PRGN-2012, which is not yet approved.
- Regulatory Milestone: The primary catalyst is the FDA decision on the PRGN-2012 BLA, expected by August 27, 2025. Approval is required to generate significant revenue and alleviate liquidity concerns.
- Capital Needs: The Company may need to raise additional capital through equity, debt, or strategic transactions. Such financings could result in significant dilution to existing shareholders.
- Strategic Focus: The Company has paused enrollment in several UltraCAR-T clinical trials (PRGN-3005, PRGN-3007) to focus resources on PRGN-2012 and PRGN-2009 (in collaboration with NCI).
- Legal Proceedings: The Company is involved in derivative shareholder actions and indemnification obligations related to the sale of Trans Ova, though management does not currently believe these will have a material adverse effect.
Investor Verification Checklist
- FDA Decision Date: Verify the status of the PRGN-2012 BLA review and the August 27, 2025 PDUFA date.
- Liquidity Runway: Assess the sufficiency of the $59.8 million cash position against projected burn rates and the likelihood of securing additional financing before approval.
- Warrant Liability Impact: Monitor the fair value of warrant liabilities, as fluctuations in stock price will continue to create significant non-cash volatility in net loss.
- Commercial Readiness: Evaluate the costs associated with the increased SG&A for commercial preparation and the timeline for potential product launch.
- Preferred Stock Terms: Review the terms of the Series A Preferred Stock, including the 8% PIK dividends and conversion features, which impact mezzanine equity and potential dilution.